Zacks Investment Research upgraded shares of ONCOTHYREON INC (ONTY) from NEUTRAL to OUTPERFORM on June 28, 2012, with a target price of $5.20.
Oncothyreon Inc., formerly Biomira Inc. is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer. The company is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Headquartered in Seattle, Washington, the primary goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer. Oncothyreon has an exclusive, worldwide collaboration agreement with Merck KGaA of Darmstadt, Germany, for the development and commercialization of Stimuvax. Its pipeline of clinical and preclinical-stage small molecule product candidates includes PX-12, PX-478 and PX-866, from ProlX Pharmaceuticals Corporation.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ONCOTHYREON INC (ONTY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment